Amsino Medical Group announces transformational investment from Novo Tellus
Summary
Were proud of the long-term relationships we have with healthcare customers around the world, and were investing in research and advanced manufacturing to bring better and better solutions to market over time," added Dr. Lee.Novo Tellus Managing Partner Loke Wai San said, "weve been long-term believers in Amsinos approach of delivering critical medical consumables to valued customers around the world. With its US headquarters, established branded offerings, and deep experience in US and Asia operations, Amsino is strategically positioned to grow into a leading supplier of diversified medical consumables worldwide. "The investment was made with all equity and no debt from Novo Tellus investment funds, and closed in June 2024, with Novo Tellus and Amsino already working actively to build the Companys future together.Amsino Medical Group, headquartered in Pomona, USA, is renowned for its comprehensive portfolio of medical devices, including urological, infusion therapy, and patient care products. To learn more about partnering with Amsino, visit amsino.com.Novo Tellus is a private equity firm focused on building lasting technology and industrial companies in Southeast Asia. The firm is distinguished by its deep insight into shifts in the global technology ecosystem, and by its active and empathic partnerships with management teams to build lasting businesses and superior investment returns.